No definition available.
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
520210 |
1. Apply sex-specific ruleNone |
520210 |
2. Check conditionsNone |
520210 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
287 |
4. Check minimum number of eventsNone |
287 |
5. Include endpointsNone |
287 |
6. Filter based on genotype QC (FinnGen only) |
287 |
Control definitions (FinnGen only)
- Control exclude
- G6_POLYNEU
Extra metadata
- Level in the ICD hierarchy
- 3
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- G62
- Name in latin
- Polyneuropathia medicamento provocata
Similar endpoints
↥List of similar endpoints to
Drug-induced polyneuropathy
based on the number of shared cases.
Similar with more cases:
- Polyneuropathies and other disorders of the peripheral nervous system
- Neurological diseases
- Neurological diseases, wide definition
- Any operation in hilmo
- Any event in hilmo or specialist outpatient
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 1549 | 841 | 700 |
| Only index persons | 1345 | 745 | 600 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.02 | 0.02 | 0.02 |
| Only index persons | 0.03 | 0.03 | 0.02 |
| Median age at first event (years) | |||
| Whole population | 62.86 | 64.41 | 60.97 |
| Only index persons | 63.08 | 64.55 | 61.25 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 287 | 149 | 138 |
| Unadjusted period prevalence (%) | 0.06 | 0.05 | 0.06 |
| Median age at first event (years) | 62.09 | 63.50 | 60.57 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS (R11)
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 266
- Matched controls
- 2658
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
G62.0
ICD-10 Finland
Drug-induced polyneuropathy
+∞
323.0
262
*
H02AB02
ATC
dexamethasone; systemic
16.3
71.7
129
145
G62.9
ICD-10 Finland
Polyneuropathy, unspecified
84.0
63.0
69
11
A04AA01
ATC
ondansetron; systemic, rectal
16.7
51.7
87
75
A03FA01
ATC
metoclopramide; systemic, rectal
7.8
47.9
140
332
117
Kela drug reimbursment
Leukaemia and other malignant diseases of the blood and bone marrow, and malignant diseases of the lymphatic tissue
20.2
46.1
71
47
N03AX16
ATC
pregabalin; oral
6.3
39.5
136
378
L03AA02
ATC
filgrastim; parenteral
22.3
36.8
54
30
128
Kela drug reimbursment
Cancers of female genital organs
41.3
36.4
45
13
ZX120
NOMESCO Finland
Intravenous
7.5
35.0
94
181
L03AA13
ATC
pegfilgrastim; parenteral
15.5
31.5
53
42
N02AA05
ATC
oxycodone; systemic
6.0
29.2
93
218
WD125
NOMESCO Finland
Demanding cystostatic therapy of methastized malignancy
13.5
29.2
52
47
WB103
NOMESCO Finland
Simple adjuvant cytostatic therapy
13.4
28.6
51
46
JN4BD
NOMESCO Finland
Extensive body CT
6.7
28.3
80
160
WB123
NOMESCO Finland
Demanding adjuvant cytostatic therapy
29.7
25.6
34
13
XW000
NOMESCO Finland
Bone marrow biopsy
9.9
23.1
48
58
WW500
NOMESCO Finland
Blood transfusion
10.1
23.1
47
55
WB113
NOMESCO Finland
Multiple adjuvant cytostatic therapy
9.5
22.7
48
60
B01AB05
ATC
enoxaparin; parenteral
3.7
21.4
133
570
C90.0
ICD-10 Finland
Multiple myeloma
33.2
21.0
27
9
L04AX04
ATC
lenalidomide; oral
62.6
20.2
23
*
153
Kela drug reimbursment
Lenalidomid
50.1
19.5
23
5
GD1AA
NOMESCO Finland
Thorax X-ray examination
3.3
19.3
164
870
TPH90
NOMESCO Finland
Removal of fixed intravenous catheter
15.1
18.8
31
23
N03AX12
ATC
gabapentin; oral
4.3
18.7
80
243
A04AA02
ATC
granisetron; systemic, transdermal
7.0
18.7
48
81
130
Kela drug reimbursment
Malignant tumour
5.8
18.2
55
115
J01EE01
ATC
sulfamethoxazole and trimethoprim; systemic
8.2
17.9
41
58
R50.9
ICD-10 Finland
Fever, unspecified
4.1
17.9
81
258
C91.0
ICD-10 Finland
Acute lymphoblastic leukaemia [ALL]
+∞
17.9
17
*
ZX112
NOMESCO Finland
Subcutaneous
11.0
17.8
34
35
WD105
NOMESCO Finland
Cystostatic therapy of methastized malignancy
9.0
17.2
37
47
C56.71
ICD-10 Finland
Serous epithelial malignant tumor of the ovary
37.8
16.9
21
6
WZC00
NOMESCO Finland
Planning of intervention or health care consultation
3.1
16.8
133
647
ZX121
NOMESCO Finland
Central venous catheter
25.0
16.7
23
10
TPX10
NOMESCO Finland
Implantation of vascular injection port
12.4
16.7
30
27
9732/3-C42.1
ICD-O-3
Plasma cell myeloma of bone marrow
40.7
15.6
19
5
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
3.8
15.5
74
244
TPH20
NOMESCO Finland
Insertion of central venous catheter through subclavian or brachiocephalic vein
10.4
15.4
30
32
WD135
NOMESCO Finland
Demanding cystostatic therapy of methastized malignancy
60.2
15.0
17
*
8461/3-C56.9
ICD-O-3
High grade serous carcinoma of ovary
+∞
14.7
14
*
LX1AE
NOMESCO Finland
Gynecological ultrasound examination as part of clinical examination
6.3
14.6
40
73
L01BC06
ATC
capecitabine; oral
8.3
14.4
32
43
TNE25
NOMESCO Finland
Drill biopsy of bone marrow, pelvis
21.5
14.0
20
10
WW300
NOMESCO Finland
Transfer of autologic stem cells
36.1
13.7
17
5
Z51.1
ICD-10 Finland
Chemotherapy session for neoplasm
14.9
13.5
22
16
TPH15
NOMESCO Finland
Insertion of central venous catheter through external or internal jugular vein
4.9
13.3
45
106
WF049
NOMESCO Finland
Radiotherapy of metastasis
9.3
13.1
27
32
A49.9
ICD-10 Finland
Bacterial infection, unspecified
4.0
13.0
55
161
R4110
NOMESCO Finland
Physiotherapy
2.8
12.8
109
531
Z94.8
ICD-10 Finland
Other transplanted organ and tissue status
33.9
12.7
16
5
ZX131
NOMESCO Finland
Intrathecal
+∞
12.6
12
*
1XX32
NOMESCO Finland
NA
136.1
12.5
13
*
JN4AD
NOMESCO Finland
Body CT examination
4.7
12.4
43
104
ZX012
NOMESCO Finland
Radiotherapy with large shaped fields - isocentric therapy
6.2
12.3
33
59
B01AB10
ATC
tinzaparin; parenteral
5.3
12.3
38
81
WD405
NOMESCO Finland
Simple antiboidy therapy of methastized malignancy
10.4
12.0
23
24
329
Kela drug reimbursment
Lenalidomide
68.0
11.7
13
*
WW402
NOMESCO Finland
Leucoferesis
68.0
11.7
13
*
N06AX21
ATC
duloxetine; oral
4.1
11.7
47
131
TAB00
NOMESCO Finland
Lumbar puncture
7.1
11.6
28
43
1XX02
NOMESCO Finland
NA
+∞
11.5
11
*
G62.8
ICD-10 Finland
Other specified polyneuropathies
125.2
11.5
12
*
H02AB09
ATC
hydrocortisone; systemic
7.7
11.4
26
37
JAL30
NOMESCO Finland
Omentectomy
18.0
11.3
17
10
C54.11
ICD-10 Finland
Adenocarcinoma of the endometrium
9.5
11.0
22
25
XX3DW
NOMESCO Finland
Time consuming IT work
3.8
10.9
48
145
WD115
NOMESCO Finland
Multiple cystostatic therapy of methastized malignancy
11.9
10.7
19
17
J05AB11
ATC
valaciclovir; oral
3.4
10.7
57
198
Z51.5
ICD-10 Finland
Palliative care
4.9
10.6
35
80
WD415
NOMESCO Finland
Demanding antibody therapy of methastized malignancy
10.2
10.5
20
21
L01BB02
ATC
mercaptopurine; oral
34.0
10.4
13
*
N02AB03
ATC
fentanyl; nasal, sublingual, transdermal
6.6
10.3
26
43
A04AA55
ATC
palonosetron, combinations; systemic
7.8
10.2
23
32
DM1AA
NOMESCO Finland
Paranasal sinuses X-ray examination without contrast
7.8
10.2
23
32
WZC20
NOMESCO Finland
Multidisciplinary treatment meeting
5.1
10.1
32
70
C83.31
ICD-10 Finland
Diffuse lymphoma with large B cells
27.2
9.9
13
5
R19.0
ICD-10 Finland
Intra-abdominal and pelvic swelling, mass and lump
8.9
9.7
20
24
JN3BD
NOMESCO Finland
Extensive abdominal CT
3.4
9.5
47
156
3AA13
NOMESCO Finland
NA
103.5
9.5
10
*
D70.82
ICD-10 Finland
Drug-induced neutropenia
9.2
9.5
19
22
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
2.3
9.2
110
616
A02BC02
ATC
pantoprazole; systemic
2.3
9.2
187
1346
L02BG04
ATC
letrozole; oral
4.5
9.2
32
78
AA1CG
NOMESCO Finland
Extensive MRI examination of brain with high intensity magnet
3.7
9.2
40
120
WX602
NOMESCO Finland
Repeated or continuing anesthesia shots throug a catheter
4.4
9.2
33
83
WD515
NOMESCO Finland
Demanding therapy of malignancy with enzyme inhibitors and similar treatments
38.1
9.1
11
*
WX408
NOMESCO Finland
General anesthesy, balanced
2.4
9.1
101
546
A04AD12
ATC
aprepitant; systemic
10.0
8.9
17
18
N02AX02
ATC
tramadol; systemic, rectal
2.2
8.8
128
785
PJD63
NOMESCO Finland
Laparoscopic dissection of aortic lymph nodes
28.5
8.5
11
*
XF400
NOMESCO Finland
ECG with 12 standard connections
2.6
8.5
68
307
393
Kela drug reimbursment
Pomalidomide
+∞
8.4
8
*
1507
Kela drug reimbursment
Pomalidomide
+∞
8.4
8
*
WW200
NOMESCO Finland
Immunization
6.5
8.0
20
33
J01MA12
ATC
levofloxacin; systemic
2.6
7.9
63
284
WX404
NOMESCO Finland
Intravenous generell anesthesy
2.4
7.9
80
409
PJD64
NOMESCO Finland
Laparoscopic dissection of iliac lymph nodes
9.9
7.9
15
16
J05AB01
ATC
aciclovir; systemic
2.5
7.7
67
316
M04AA01
ATC
allopurinol; systemic
2.9
7.7
48
188
TPH04
NOMESCO Finland
Cathetrisation of vein
2.4
7.6
76
386
WX302
NOMESCO Finland
Thoracal epidural anesthesy
4.2
7.5
28
73
WF003
NOMESCO Finland
Adjuvant radiotherapy
6.3
7.5
19
32
A05AA02
ATC
ursodeoxycholic acid; oral
8.0
7.5
16
21
YNB10
NOMESCO Finland
Collection of stem cells for transplant
82.3
7.5
8
*
J01DB01
ATC
cefalexin; oral
2.4
7.4
220
1776
JAL31
NOMESCO Finland
Laparoscopic omentectomy
+∞
7.3
7
*
9835/3-C42.1
ICD-O-3
Precursor cell lymphoblastic leukemia, NOS, of bone marrow
+∞
7.3
7
*
ZX080
NOMESCO Finland
Image guided radiotherapy
7.7
7.3
16
22
B03XA01
ATC
erythropoietin; parenteral
16.3
7.3
11
7
WD325
NOMESCO Finland
Demanding therapy of methastized malignancy with biomodifiers
20.7
7.2
10
5
N06AA09
ATC
amitriptyline; systemic
3.2
7.2
37
127
R10.4
ICD-10 Finland
Other and unspecified abdominal pain
2.1
7.2
105
629
ZXM00
NOMESCO Finland
Intraoperative use of ultrasonographic imaging
14.3
6.9
11
8
EB1HA
NOMESCO Finland
Panorama tomography of teeth and jaws or similar X-ray examination
2.0
6.9
120
772
N03AX09
ATC
lamotrigine; oral
5.2
6.8
20
41
127
Kela drug reimbursment
Transplant complication
7.5
6.8
15
21
H02AB06
ATC
prednisolone; systemic
2.0
6.8
133
890
LAF16
NOMESCO Finland
Excision of uterus, adnexes and lymph nodes for treatment of ovarian cancer
23.2
6.7
9
*
ZX108
NOMESCO Finland
Inhalation
12.7
6.6
11
9
YG1BD
NOMESCO Finland
Extensive CT examination of thorax for dose design of radiotherapy
5.3
6.6
19
38
UJF32
NOMESCO Finland
Coloscopy
2.2
6.6
81
446
N05CF01
ATC
zopiclone; oral
2.1
6.6
91
530
N06AX16
ATC
venlafaxine; oral
2.8
6.6
44
176
LAF11
NOMESCO Finland
Laparoscopic bilateral salpingo-oophorectomy
4.3
6.6
23
57
GD1PA
NOMESCO Finland
X-ray examination of the lungs in one projection
2.8
6.5
41
160
A06AD11
ATC
lactulose; oral
2.6
6.5
48
207
WF004
NOMESCO Finland
Palliative radiotherapy
7.7
6.5
14
19
GD1UA
NOMESCO Finland
Thorax X-ray examination outside radiological department
2.4
6.5
60
292
NJ3DA
NOMESCO Finland
Long bones of extremities X-ray examination
14.8
6.4
10
7
ZX114
NOMESCO Finland
Intramuscular
6.2
6.4
16
27
J18.9
ICD-10 Finland
Pneumonia, unspecified
2.1
6.3
76
417
6BA02
NOMESCO Finland
NA
18.5
6.3
9
5
C79.8
ICD-10 Finland
Secondary malignant neoplasm of other specified sites
4.5
6.3
21
50
L04AX06
ATC
pomalidomide; oral
+∞
6.3
6
*
X77
ICPC
Malignant neopl genital female other
+∞
6.3
6
*
WX2DD
NOMESCO Finland
Low-dose CT of skeleton in whole body
+∞
6.3
6
*
115
Kela drug reimbursment
Breast cancer
3.1
6.2
33
116
GD1BD
NOMESCO Finland
Thorax extensive CT-examination
3.6
6.1
26
77
NA7DG
NOMESCO Finland
Spine and spinal cord very extensive MRI examination with high intensity magnet
12.9
6.1
10
8
FM2CE
NOMESCO Finland
NA
5.4
6.1
17
33
R1230
NOMESCO Finland
Neuropsychological evaluation of need and possibilities to rehabilitation
8.9
6.1
12
14
Y57
ICD-10 Finland
Adverse effects in the therapeutic use of other and unspecified drugs and medicaments
7.0
6.1
14
21
LCD01
NOMESCO Finland
Total laparoscopic hysterectomy
6.3
6.1
15
25
ZXC96
NOMESCO Finland
Robot assisted procedure
6.3
6.1
15
25
C18.71
ICD-10 Finland
Malignant tumor of the sigmoid invasive carcinoma
10.4
6.1
11
11
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
84
203
5.44
34.38
10.3
2.5
65.0
65.7
g/l
0.38
77
187
226
1270
4.67
27.89
19.1
6.4
9.8
11.3
umol/l
2.49
220
1202
89
288
4.03
24.39
11.7
4.0
253.5
243.0
u/l
0.29
89
276
191
1034
3.53
23.05
13.0
5.2
34.4
35.4
g/l
1.80
183
964
233
1454
4.20
22.04
38.5
10.0
3.5
4.1
e9/l
3.85
217
1249
34
54
7.01
21.06
10.2
10.3
200.8
129.8
iu/ml
—
6
11
81
271
3.77
20.84
6.2
4.0
4.8
24.4
ug/l
0.68
68
226
39
79
5.56
18.90
14.0
1.3
8.8
10.6
g/l
1.75
32
73
40
84
5.37
18.63
13.7
1.3
—
—
—
0
0
40
84
5.37
18.63
13.7
1.3
6.9
7.5
g/l
1.31
27
70
40
84
5.37
18.63
13.7
1.3
3.9
3.7
g/l
0.11
26
67
93
369
3.25
18.04
13.6
7.2
1.1
1.1
mmol/l
1.26
86
344
155
827
2.90
17.57
7.3
3.3
2.4
2.4
mmol/l
0.09
141
717
90
362
3.17
16.93
3.0
2.5
2.3
2.4
g/l
0.69
84
334
36
77
5.20
16.38
14.1
1.6
1.9
0.4
g/l
1.11
28
70
36
78
5.13
16.13
13.6
1.3
2.9
3.2
g/l
1.35
28
68
259
1896
4.75
16.07
20.0
7.2
88.6
86.4
u/l
0.29
253
1759
194
1203
2.89
15.94
16.4
6.5
1.2
1.2
mmol/l
0.72
182
1098
93
393
3.02
15.94
2.5
1.9
—
—
—
0
0
202
1293
2.90
15.38
18.1
7.6
1.2
1.2
mmol/l
1.38
175
1116
141
755
2.71
15.29
4.8
2.4
54.9
56.0
u/l
0.10
130
690
85
350
3.03
15.17
3.2
2.6
22.4
21.4
%
0.26
77
307
54
175
3.57
14.21
2.0
1.8
—
—
—
0
0
32
70
5.02
14.15
3.0
2.3
14.1
19.5
iu/l
0.50
20
52
214
1444
2.89
14.15
11.1
5.0
6.5
6.7
mmol/l
0.66
207
1361
19
8
25.30
13.98
1.2
1.6
—
—
—
0
0
188
1202
2.64
13.61
23.1
6.7
55.7
55.9
%
0.08
181
1130
19
26
7.75
13.28
7.2
3.9
—
—
—
0
0
32
74
4.74
13.24
3.2
2.1
8.3
7.8
u/l
0.07
18
55
16
18
9.35
13.01
4.9
6.2
—
—
—
0
0
16
18
9.35
13.01
4.9
6.2
—
—
—
0
0
188
1222
2.56
12.82
24.2
6.9
27.9
29.0
%
0.53
181
1140
31
72
4.71
12.75
14.7
1.3
37.9
37.2
g/l
0.34
25
66
69
282
2.90
12.24
2.7
1.9
—
—
—
0
0
173
1097
2.45
12.23
8.1
4.1
—
—
—
0
0
66
264
2.95
12.17
3.0
2.8
0.2
0.2
g/l
0.06
66
248
21
36
6.21
11.97
4.0
1.6
—
—
—
0
0
119
649
2.42
11.67
7.9
2.7
326.2
6587.3
umol/l
2.84
112
553
68
285
2.82
11.46
2.8
1.9
—
—
—
0
0
70
300
2.76
11.29
9.3
3.6
8.1
8.8
umol/l
0.09
61
263
59
234
2.92
10.98
3.4
2.2
27.7
28.5
u/l
0.09
52
196
13
14
9.68
10.84
3.0
4.2
—
—
—
0
0
28
69
4.39
10.69
3.7
2.9
—
—
—
0
0
88
437
2.46
10.42
4.9
3.4
1.4
2.4
e6/l
0.91
66
247
25
58
4.63
10.27
2.0
1.3
—
—
—
0
0
25
58
4.63
10.27
2.0
1.3
—
—
—
0
0
29
76
4.13
10.22
1.3
1.3
—
—
—
0
0
151
952
2.24
10.16
6.1
3.5
—
—
—
0
0
217
1601
2.46
9.86
7.1
4.6
11.3
2443.0
e6/l
—
7
32
24
57
4.50
9.58
3.6
1.6
—
—
—
0
0
124
751
2.15
8.92
6.0
3.5
0.4
0.4
e6/l
0.01
107
571
98
543
2.22
8.80
5.7
1.9
2.4
1.3
mg/l
0.43
77
437
27
75
3.87
8.79
3.5
1.8
—
—
—
0
0
150
981
2.11
8.78
4.2
2.8
226.1
135.4
ug/l
1.64
137
898
14
22
6.64
8.61
1.2
1.2
—
—
—
0
0
21
49
4.55
8.55
3.6
1.6
—
—
—
0
0
27
78
3.72
8.32
3.4
1.7
—
—
—
0
0
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
25
69
3.87
8.21
2.8
2.4
0.3
0.4
u/ml
0.38
12
35
144
950
2.04
8.00
2.4
1.9
95.5
94.6
pmol/l
0.07
91
462
84
464
2.15
7.43
4.8
3.0
1.0
1.0
e6/l
0.06
61
273
119
755
1.98
7.18
4.0
3.3
863.2
1222.1
ng/l
1.01
108
646
44
187
2.60
7.05
26.0
6.9
24.4
23.9
mmol/l
0.62
44
178
49
221
2.47
6.94
7.5
7.6
1.3
1.3
mmol/l
0.03
44
205
51
238
2.39
6.70
3.9
3.6
—
—
—
0
0
97
587
1.99
6.60
5.5
2.5
—
—
—
0
0
20
55
3.83
6.60
1.6
2.1
205.3
232.6
u/ml
0.11
15
26
13
25
5.40
6.55
2.4
1.4
—
—
—
0
0
10
7
14.74
6.44
5.1
4.9
—
—
—
0
0
20
56
3.76
6.44
1.5
2.1
—
—
—
0
0
35
139
2.73
6.40
2.0
1.7
—
—
—
0
0
98
606
1.94
6.20
2.3
2.5
3.1
3.1
mg/l
0.02
91
526
58
296
2.20
6.17
20.4
6.5
1.9
1.8
mmol/l
0.07
51
226
141
990
1.83
5.94
3.0
2.6
76.8
77.6
nmol/l
0.11
129
882
19
55
3.63
5.84
1.3
1.1
—
—
—
0
0
9
7
13.22
5.62
2.9
9.3
—
—
—
0
0
220
1806
1.93
5.29
6.3
4.3
15.0
12.2
mm/h
1.42
205
1650
131
923
1.77
5.28
3.8
3.9
25.4
41.6
ng/l
1.52
101
678
190
1498
1.79
5.11
5.1
3.3
90.0
52.0
u/l
1.26
176
1381
75
449
1.91
5.11
1.8
1.7
1074.9
1188.8
nmol/l
0.43
53
333
8
6
13.66
5.11
3.0
6.7
—
—
—
0
0
8
6
13.66
5.11
3.0
6.7
—
—
—
0
0
90
575
1.82
4.99
1.8
1.5
19.9
22.0
nmol/l
0.57
81
479
42
205
2.23
4.95
2.7
2.2
8.8
13.0
nmol/l
2.27
25
178
17
54
3.28
4.56
1.8
1.4
—
—
—
0
0
53
293
1.99
4.52
25.8
20.0
1.3
1.2
inr
—
5
38
50
273
2.01
4.41
6.2
7.1
0.5
1.3
mmol/l
0.91
40
223
11
26
4.36
4.39
1.5
1.2
—
—
—
0
0
10
22
4.67
4.33
1.0
1.0
—
—
—
0
0
19
68
2.92
4.21
1.4
1.5
—
—
—
0
0
33
156
2.26
4.19
1.9
1.4
—
—
—
0
0
104
725
1.68
4.12
2.6
2.1
133.8
208.8
u/l
1.56
97
686
9
14
6.60
4.01
1.9
1.1
—
—
—
0
0
73
466
1.76
3.96
5.7
3.7
25.2
248.7
ng/l
2.59
63
383
18
66
2.84
3.83
1.4
1.2
—
—
—
0
0
265
2403
2.34
3.76
39.0
14.8
26.4
24.3
mg/l
0.49
240
1859
155
1215
1.60
3.74
4.7
3.9
0.0
0.0
estimate
0.00
36
222
10
25
4.11
3.73
1.6
1.6
—
—
—
0
0
21
85
2.59
3.72
2.1
2.4
—
—
—
0
0
42
229
1.98
3.71
4.5
6.0
1.9
1.5
mmol/l
0.21
31
173
152
1194
1.58
3.58
4.7
3.9
0.0
0.0
estimate
0.00
33
237
9
17
5.43
3.54
4.3
3.0
0.1
0.1
nmol/l
—
9
10
8
13
6.29
3.52
1.4
1.1
—
—
—
0
0
43
241
1.92
3.51
4.5
5.9
5.2
5.1
kpa
0.39
37
226
15
53
2.93
3.41
2.2
1.7
—
—
—
0
0
152
1203
1.56
3.40
6.2
5.3
0.0
0.0
estimate
0.00
35
232
9
19
4.85
3.26
2.9
1.1
—
—
—
0
0
7
11
6.49
3.20
1.4
1.5
—
—
—
0
0
7
11
6.49
3.20
1.4
1.5
—
—
—
0
0
9
20
4.61
3.14
4.6
1.3
0.2
0.1
nmol/l
—
9
12
12
39
3.17
3.12
2.1
1.7
—
—
—
0
0
7
12
5.95
3.04
1.4
1.4
—
—
—
0
0
7
12
5.95
3.04
1.4
1.4
—
—
—
0
0
5
5
10.14
2.99
1.2
1.2
—
—
—
0
0
18
76
2.46
2.96
1.7
1.8
—
—
—
0
0
17
70
2.52
2.94
1.4
1.4
254.6
292.7
ug/g
0.33
12
37
7
15
4.75
2.61
1.0
1.1
—
—
—
0
0
7
15
4.75
2.61
4.4
3.5
94.7
96.7
%
—
7
15
9
25
3.68
2.59
5.1
2.9
53.7
59.7
u/ml
—
9
25
9
25
3.68
2.59
1.1
1.2
—
—
—
0
0
35
203
1.82
2.59
5.7
2.9
67.1
62.3
ml/min/173m2
—
10
81
208
1827
1.50
2.44
4.9
3.9
14.8
14.8
pmol/l
0.18
191
1645
10
34
3.01
2.43
2.3
1.8
—
—
—
0
0
18
84
2.22
2.40
1.8
2.0
—
—
—
0
0
7
17
4.19
2.37
1.0
1.8
—
—
—
0
0
11
42
2.68
2.21
2.5
1.7
—
—
—
0
0
6
14
4.35
2.16
2.0
2.6
811.0
816.6
u/ml
—
6
14
8
26
3.13
2.03
1.1
1.5
—
—
—
0
0
9
33
2.78
1.95
1.1
1.3
—
—
—
0
0
25
144
1.81
1.92
1.2
1.4
—
34.0
—
0
12
34
215
1.66
1.90
4.8
5.2
108.6
72.3
ng/l
0.74
27
190
7
22
3.23
1.89
1.0
1.0
—
—
—
0
0
236
2168
1.50
1.86
35.4
13.8
77.4
78.5
ml/min/173m2
0.36
218
1790
(3016894) Varicella zoster virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection
6
17
3.58
1.84
1.5
1.1
—
—
—
0
0
7
23
3.09
1.81
1.0
1.3
690.7
225.6
u/l
—
7
23
7
23
3.09
1.81
1.0
1.0
—
—
—
0
0
13
60
2.22
1.80
1.7
1.4
—
—
—
0
0
17
88
1.99
1.79
1.4
2.3
—
—
—
0
0
7
25
2.84
1.66
1.9
1.1
—
—
—
0
0
235
2174
1.45
1.62
49.7
16.3
37.3
39.8
%
3.62
155
1581
5
14
3.61
1.62
4.4
1.6
—
—
—
0
0
10
43
2.37
1.62
2.8
1.7
—
—
—
0
0
5
15
3.37
1.53
3.2
1.7
—
—
—
0
0
5
15
3.37
1.53
2.0
1.1
—
—
—
0
0
5
15
3.37
1.53
4.4
1.6
—
—
—
0
0
268
2556
1.73
1.52
31.6
10.8
27.3
25.8
u/l
0.79
263
2460
9
38
2.41
1.47
3.0
1.7
—
—
—
0
0
82
656
1.35
1.46
5.1
4.2
0.0
0.0
estimate
0.00
33
231
5
17
2.97
1.36
4.4
1.6
—
—
—
0
0
5
17
2.97
1.36
2.8
3.1
29.0
25.2
umol/l
—
5
17
5
18
2.81
1.29
2.0
1.4
—
—
—
0
0
66
521
1.35
1.27
1.8
1.8
414.4
444.6
pmol/l
0.50
52
430
6
25
2.43
1.25
1.5
1.2
—
—
—
0
0
6
25
2.43
1.25
1.0
1.0
—
—
—
0
0
9
45
2.03
1.24
1.1
1.4
—
—
—
0
0
30
206
1.51
1.23
2.2
2.6
11.0
8.3
ug/l
0.19
24
182
5
19
2.66
1.22
1.0
1.2
—
—
—
0
0
5
22
2.29
1.04
5.2
1.5
—
—
—
0
0
5
22
2.29
1.04
1.4
1.7
—
—
—
0
0
7
34
2.08
1.03
1.4
1.1
—
—
—
0
0
38
285
1.38
1.02
1.7
1.4
—
—
—
0
0
106
919
1.24
0.99
4.9
4.0
—
—
—
0
0
234
2215
1.31
0.97
5.8
4.6
2.1
2.0
mu/l
0.51
212
2002
39
298
1.36
0.94
7.9
7.2
—
—
—
0
0
14
86
1.66
0.92
1.2
1.1
—
—
—
0
0
14
86
1.66
0.92
1.2
1.1
—
—
—
0
0
11
64
1.75
0.87
1.8
1.3
—
—
—
0
0
8
137
0.57
0.85
1.8
1.6
—
—
—
0
0
233
2217
1.27
0.83
4.8
4.2
1.5
1.3
mmol/l
3.16
211
2017
241
2303
1.29
0.83
5.0
4.7
4.6
4.6
mmol/l
0.15
219
2111
6
32
1.89
0.82
1.0
1.1
—
—
—
0
0
12
187
0.63
0.81
3.2
1.8
—
—
—
0
0
9
150
0.59
0.81
2.1
1.8
—
—
—
0
0
86
749
1.21
0.75
4.2
4.0
10.0
31.8
mg/mmol
0.44
51
471
19
136
1.43
0.69
1.1
1.2
—
96.1
iu/ml
—
0
47
5
27
1.87
0.68
1.2
1.2
—
—
—
0
0
5
27
1.87
0.68
1.2
1.2
—
—
—
0
0
5
28
1.80
0.66
1.2
1.2
—
—
—
0
0
5
28
1.80
0.66
1.2
1.2
—
—
—
0
0
5
28
1.80
0.66
1.2
1.2
—
—
—
0
0
5
29
1.74
0.64
1.4
1.1
—
—
—
0
0
49
415
1.22
0.57
1.7
1.6
—
—
—
0
0
6
36
1.68
0.57
1.8
3.9
—
—
—
0
0
237
2290
1.20
0.53
4.9
4.6
1.4
1.5
mmol/l
2.49
214
2084
75
670
1.16
0.49
1.8
1.6
1.4
1.3
mmol/l
0.61
61
563
16
121
1.34
0.45
1.2
1.2
—
—
—
0
0
231
2237
1.17
0.45
6.0
6.0
39.7
40.2
mmol/mol
0.28
208
2072
13
95
1.39
0.44
1.7
1.6
—
—
—
0
0
0
15
0.00
0.41
0.0
1.9
—
—
—
0
0
8
59
1.37
0.41
1.3
1.3
—
—
—
0
0
5
35
1.44
0.39
2.2
1.5
—
—
—
0
0
5
35
1.44
0.39
2.2
1.5
—
—
—
0
0
5
35
1.44
0.39
2.2
1.5
—
—
—
0
0
5
35
1.44
0.39
2.2
1.5
—
—
—
0
0
5
35
1.44
0.39
2.2
1.5
—
—
—
0
0
5
36
1.40
0.38
2.2
1.5
—
—
—
0
0
5
37
1.36
0.37
1.2
1.1
—
—
—
0
0
16
126
1.29
0.36
6.8
4.4
1.2
1.2
%
0.01
16
126
64
581
1.13
0.34
1.3
1.4
1.0
1.5
u/ml
0.37
13
142
54
485
1.14
0.34
3.1
3.0
1.0
0.8
ug/l
0.30
38
312
7
53
1.33
0.31
2.1
1.8
169.3
228.2
pmol/l
—
7
47
150
1436
1.09
0.29
2.8
2.8
—
—
—
0
0
239
2347
1.11
0.23
5.3
5.3
2.7
2.7
mmol/l
0.17
217
2142
0
10
0.00
0.21
0.0
1.8
—
—
—
0
0
5
43
1.17
0.21
1.2
1.1
—
—
—
0
0
234
2302
1.09
0.19
5.1
4.7
6.0
6.0
mmol/l
0.27
212
2083
10
81
1.24
0.19
1.2
1.1
—
—
—
0
0
7
62
1.13
0.17
1.1
1.3
—
—
—
0
0
8
68
1.18
0.16
1.1
1.4
—
—
—
0
0
32
305
1.06
0.06
4.7
4.6
30.1
32.0
%
0.45
19
196
65
665
0.97
0.05
3.7
4.5
22.5
21.1
%
0.16
25
316
85
835
1.03
0.04
6.0
5.0
3.0
2.7
ug/l
0.12
73
752
37
382
0.96
0.04
1.4
1.3
5.4
8.9
u/ml
0.30
15
140
40
398
1.01
0.00
1.5
1.3
69.8
32.3
iu/ml
—
8
133
14
141
0.99
0.00
1.0
1.1
—
—
—
0
0
0
9
0.00
0.00
0.0
1.1
—
—
—
0
0
0
9
0.00
0.00
0.0
1.2
—
—
—
0
0
0
9
0.00
0.00
0.0
1.1
—
—
—
0
0
0
9
0.00
0.00
0.0
1.1
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
0.00
0.0
3.3
—
71.6
—
0
7
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint G6_DRUGPOLY and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| G6_DRUGPOLY | 4.185 [3.26, 5.37] | < 0.001 |
| Birth year | 0.996 [0.98, 1.01] | 0.502 |
During the follow-up period (1.1.1998 — 31.12.2019), 289 out of 698 females with G6_DRUGPOLY died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| G6_DRUGPOLY | 2.961 [2.28, 3.84] | < 0.001 |
| Birth year | 0.99 [0.98, 1.0] | 0.032 |
During the follow-up period (1.1.1998 — 31.12.2019), 218 out of 581 males with G6_DRUGPOLY died.
Mortality risk
Mortality risk for people of age
years, who have G6_DRUGPOLY.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.486% | 0.586% |
| 5 | 2.514% | 3.499% |
| 10 | 6.052% | 8.655% |
| 15 | 11.118% | 16.382% |
| 20 | 19.482% | 27.032% |
Relationships between endpoints
↥Index endpoint: G6_DRUGPOLY – Drug-induced polyneuropathy
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data